Shares of GRAIL, Inc. (NASDAQ: GRAL) surged 22.53% during intraday trading on Tuesday following the release of the company's first-quarter 2025 financial results and positive data from its cancer detection trials.

GRAIL, a healthcare company focused on early cancer detection through blood testing, reported Q1 revenue of $31.8 million, representing a 19% year-over-year growth. The company's flagship product, Galleri, saw its revenue increase by 24% to $29.1 million. Despite posting a net loss of $106.2 million for the quarter, investors were encouraged by the strong top-line growth and the company's improving financial position.

Adding to the optimism, GRAIL announced positive top-line results from the prevalent screening round of the NHS-Galleri trial. The company reported a substantially higher positive predictive value (PPV) than previously observed in the PATHFINDER study. This data suggests improved accuracy in GRAIL's multi-cancer early detection (MCED) technology, potentially strengthening its position in the cancer diagnostics market. The company plans to share registrational data from the PATHFINDER 2 study later this year, further fueling investor enthusiasm about GRAIL's future prospects in early cancer detection.